Active substance (DCI)
- obinutuzumab
history (3)
-
4/18/18
GAZYVARO (obinutuzumab)
CAV : -
3/8/17GAZYVARO (obinutuzumab), monoclonal antibody
CAV : -
2/18/15GAZYVARO (obinutuzumab), type II humanised anti-CD20 recombinant monoclonal antibody
CAV :
